Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

BROKERS - Wunderlich shoots down rating on Smith & Wesson

A look at some analyst takes on US companies on Thursday

Gun maker Smith & Wesson (NYSE:SWHC) gets shot down today by Wunderlich, which moves the share to 'hold' from 'buy' and downgrades the price target to US$29 from US$36.

Shares today dropped 3.53% to US$25.23.

Orion Group (LON:ORN) is also on the analyst radar today. The firm is upgraded to 'outperform' from 'marketperform' by FBR & Co, while the price target is punched up to US$9 from US$6.

Boeing (NYSE:BA) has been initiated by Robert W Baird as an 'outperform' and US$161 price target - current price US$134.77.

It comes as the plane maker and engineer said it delivered fewer planes in the third quarter - 188 craft compared to 199 in the same period last year.

Boeing booked orders for 150 commercial planes in the third quarter, lower than the 182 a year earlier.

The same broker also starts covering heating engineering giant Honeywell (NYSE:HON) with an 'outperform' stance and US$135 target.

Elsewhere, broker Wedbush rates medical technology group Novadaq Technologies (NVDQ) as 'outperform', saying it sees the firm's growth in the near term to be driven by the breast reconstruction market.

"Novadaq's SPY fluorescence imaging technology has rapidly emerged as a critical intraoperative diagnostic tool during breast reconstruction surgery, and our proprietary surgeon survey suggests the technology should gain greater adoption, potentially becoming standard of care within the next 5 years," said the broker in a note.

The technology allows medics to see blood flow in vessels, micro-vessels, tissue perfusion and other structures in treatment.

Wedbush puts a US$17 price target (12 months) on the shares, which is a good distance from the current price of US$11.32.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK